W
Wen Zhang
Researcher at Second Military Medical University
Publications - 4
Citations - 822
Wen Zhang is an academic researcher from Second Military Medical University. The author has contributed to research in topics: Receptor tyrosine kinase & Receptor. The author has an hindex of 3, co-authored 4 publications receiving 532 citations.
Papers
More filters
Journal ArticleDOI
Chalcone: A Privileged Structure in Medicinal Chemistry.
TL;DR: This review aims to highlight the recent evidence of chalcone as a privileged scaffold in medicinal chemistry and is expected to be a comprehensive, authoritative, and critical review of the chal cone template to the chemistry community.
Journal ArticleDOI
ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling
Jin Ding,Wen Wen,Xiang Daimin,Peipei Yin,Yanfang Liu,Chang Liu,Guoping He,Zhuo Cheng,Jianpeng Yin,Chunquan Sheng,Wen Zhang,Fajun Nan,Wen-Cai Ye,Xiuli Zhang,Hongyang Wang +14 more
TL;DR: π-Bufarenogin, a novel active compound isolated from the extract of toad skin, exhibited potent therapeutic effect in xenografted human hepatoma without notable side effects and could be a novel lead compound for anti-HCC drug.
Journal ArticleDOI
A novel drug discovery strategy: mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF-κB pathways.
Chunlin Zhuang,Chunquan Sheng,Woo Shik Shin,Yuelin Wu,Jin Li,Jianzhong Yao,Guoqiang Dong,Wen Zhang,Yuk Y. Sham,Zhenyuan Miao,Wannian Zhang +10 more
TL;DR: An antitumor molecule that bears a pyrrolo[3,4-c]pyrazole scaffold and functions as an enantiomersic inhibitor against both the p53-MDM2 interaction and the NF-κB activation is reported, a first-in-class enantiomeric inhibitor with dual efficacy for cancer therapy.